Abstract
Background The impact of COVID-19 across the United States has been heterogeneous, with some areas demonstrating more rapid spread and greater mortality than others. We used geographically-linked data to test the hypothesis that the risk for COVID-19 is spatially defined and sought to define which features are most closely associated with elevated COVID-19 spread and mortality.
Methods Leveraging geographically-restricted social, economic, political, and demographic information from U.S. counties, we developed a computational framework using structured Gaussian processing to predict county-level case and death counts during both the initial and the nationwide phases of the pandemic. After identifying the most predictive spatial features, we applied an unsupervised clustering algorithm, topic modelling, to identify groups of features that are most closely associated with COVID-19 spread.
Findings We found that the inclusion of spatial features modeled case counts very well, with overall Pearson’s correlation coefficient (PCC) and R2of 0.96 and 0.84 during the initial phase and 0.95 and 0.87, respectively, during the nationwide phase. The most frequently selected features were associated with urbanicity and 2020 presidential vote margins. When trained using death counts, models revealed similar performance metrics, with the addition of aging metrics to those most frequently selected. Topic modeling showed that counties with similar socioeconomic and demographic features tended to group together, and some feature sets were associated with COVID-19 dynamics. Unsupervised clustering of counties based on these topics revealed groups of counties that experienced markedly different COVID-19 spread.
Interpretation Spatial features explained most of the variability in COVID-19 dynamics between counties. Topic modeling can be used to group collinear features and identify counties with similar features in epidemiologic research.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
his work was supported by funding from the Cancer Early Detection Advanced Research Center at the Knight Cancer Institute, Oregon Health & Science University (CA, ADC, RE, and AJG) and the National Cancer Institute (K08 CA245188) awarded to AJG.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used in this manuscript are publicly available. We retrieved county-level daily case counts from the Center for Systems Science and Engineering at Johns Hopkins University. We extracted county-specific features from the United States Census Bureau and the National Center for Health Statistics population estimates. County-specific features used in this study are shown in Table S1 along with the source information.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are publicly available online at the sources identified in Table S1.
